Kornimate/medical-research-clean huggingface dataset:
study of adalimumab in subjects with moderate to severe chronic hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: this study will investigate how well adalimumab works in people with hidradenitis suppurativa (hs) in the short and long term.

this phase 2 randomized, double-blind, placebo-controlled multicenter study consists of 2 treatment periods: a 16-week double-blind, placebo-controlled period (period 1: weeks 0 through the end of week 15) followed by a 36-week open-label period (period 2: weeks 16 through 52). participants are randomized in a 1:1:1 ratio based on hurley stage as stratification factor to receive adalimumab 40 mg every week (qwk), adalimumab 40 mg every other week (eow), or matching placebo during period 1. during period 2, participants receive open-label adalimumab 40 mg eow with the option to escalate to 40 mg weekly dosing at week 28 or week 31 if the participant has a physician's global assessment of moderate disease or worse (score of greater than or equal to 3). the primary objective of the study is to determine the clinical efficacy and safety of participants with moderate to severe chronic hidradenitis suppurativa (hs) after 16 weeks of treatment. the secondary objective is to evaluate the maintenance of efficacy and continued safety of adalimumab for an additional 36 weeks of treatment. (note: hurley stage is a classification system for skin involvement that is largely based on the presence and extent of abscess formation accompanied by scarring and sinus tracts. hurley stages are i \[abscess formation without scarring and sinus tracts\], ii \[widely separated recurrent abscesses with scarring and sinus tracts\], and iii \[multiple interconnected abscesses and sinus tracts across entire area\]. randomization in this study was performed using stratification by hurley stage \[iii versus (i or ii).) at the present time, period 1 double-blind data only is provided; additional information will be provided when analysis of open-label period 2 is completed.

Eligibility criteria:
inclusion criteria: * adults with stable, moderate to severe hidradenitis suppurativa * negative chest x-ray and ppd test at screening. if participant has had a past ulcerative reaction to ppd placement and/or chest x-ray consistent with prior tuberculosis exposure, the participant must initiate, or have documented completion of, a course of anti-tuberculosis therapy. * ability to administer subcutaneous injections * general good health otherwise exclusion criteria: * prior anti-tnf therapy * unstable antibiotic therapy for hs * required medication washouts for other hs treatments * prior exposure to tysabri® (natalizumab); * recent infection requiring treatment * significant medical events or conditions that may put patients at risk for participation * female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study; * history of cancer, except successfully treated skin cancer * recent history of drug or alcohol abuse

Keywords: hidradenitis suppurativa adalimumab nodule abscess fistula physicians global assessment hurley stage sartorius scale
the effect of chiropractic plus nutritional supplement in patients with chronic pain and inflammation.

Conditions: Chronic Pain; Inflammatory Response

Summary: evaluating the effect of a combined therapy of chiropractic sessions plus nutritional supplement containing hemp, omega-3 fatty acids, and broccoli extract oil in patients experiencing chronic pain and inflammation.


Eligibility criteria:
inclusion criteria: * chronic pain (\>3years) exclusion criteria: * gaba/opioid medication
magnetic resonance imaging (mri) using liverspecific oral contrast agent in metastatic colorectal cancer patients

Conditions: Neoplasm Metastasis; Liver; Colorectal Neoplasms; Magnetic Resonance Imaging; Contrast Media

Summary: the purpose of this study is to determine whether mri with manganese containing contrast agent detects more livermetastasis compared to ct scan


Eligibility criteria:
inclusion criteria: * biopsy proved liver metastasis exclusion criteria: * pacemaker, metal in the body, claustrophobia, pregnancy, age below 18 years, psychiatry patients

Keywords: mri liverspecific contrast colorectal metastases
epidemiology of barrett's esophagus: a population based study

Conditions: Barrett's Esophagus; Gastroesophageal Reflux Disease (GERD); Olmsted County Resident

Summary: to assess attitudes toward screening for esophageal adenocarcinoma (eac) and barrett's esophagus (be) in the community. to develop a population based clinical risk factor prediction model for the diagnosis of be and identify novel risk factors for be which would make population based screening more efficient. this will be an important first step in identifying the target population for be screening, another crucial component of making screening feasible and efficient


Eligibility criteria:
inclusion criteria: 1. case: olmsted county residents \> 18 years old from the barrett's esophagus (be) incidence cohort who are still alive at the time of study. 2. control # 1 : olmsted county residents \> 18 years old that responded to a recent community based survey and reported gastroesophageal reflux (ger) symptoms at least once a week and without a known diagnosis of be. 3. control # 2 : olmsted county residents \> 18 years old that responded to a recent community based survey that did not report any ger symptoms and without a known diagnosis of be. exclusion criteria: 1. cases: be subjects who 1. have died prior to the start of this study; 2. refuse to participate; 2. controls: respondents to the "constipation survey" who 1. are known to have be; 2. have died prior to the start of this study; 3. refuse to participate; -

Keywords: barrett's esophagus gastroesophageal reflux disease gerd
experience of the nationwide gambling self-exclusion service spelpaus - effects and limitations of a unique harm reduction instrument for problem gambling

Conditions: Gambling Disorder; Problem Gambling

Summary: qualitative interview study addressing the effects and limitations of a unique, government-based, nationwide self-exclusion service for the reduction of gambling-related harm. this service, which allows for individuals at risk of gambling problems (and for anyone) to self-exclude from all licensed gambling in the country, is unique in its nationwide, non-gambling-operator-dependent and multi-operator design. it is a promising tool for the prevention and harm reduction in relation to problem gambling and gambling disorder, but emerging research data report considerable limitations including high access to non-licensed gambling allowing users to breach the voluntary self-exclusion and relapse into hazardous gambling practices. this study will examine effects and limitations of the system, for gamblers and for concerned significant others of gamblers, through qualitative interviews addressing their experience of the system.


Eligibility criteria:
inclusion criteria: * patient at a gambling disorder unit or self-recruited through social media advertising and defining as a person with a gambling problem, and/or concerned significant other of a patient at a gambling disorder unit or self-recruited through social media advertising and defining as a concerned significant other of a person with a gambling problem. exclusion criteria: * inability to provide informed study consent and to carry out a qualitative research interview, due to language difficulties and/or cognitive problems.

Keywords: gambling disorder problem gambling concerned significant others self-exclusion harm reduction
effectiveness study of individual online treatment for cybersex addiction/online sexual compulsive behavior disorder

Conditions: Sexual Compulsive Behavior Disorder; Cybersex Addiction; Online Compulsive Sexual Behavior

Summary: cybersex addiction, understood as a subtype of internet addiction or a manifestation of compulsive sexual behavior disorder, is a growing phenomenon. recent studies developed by our research group have revealed that about 10% of young people in spain could be at risk of suffering or already suffer from this problem, which can lead to consequences beyond the addiction or compulsive behavior itself, such as low self-esteem, emotional problems, sexual dysfunction, infidelity, breakups, social isolation, development of paraphilias, increase of risky sexual behavior, problems with the law, etc.. although some studies have been carried out so far, especially on the prevalence and characterization of the sociodemographic and psychological profile of people with this disorder, psychological intervention programs for this problem have hardly been developed, and studies on the effectiveness of such programs are very scarce. furthermore, seeking psychological help for people with this type of problem is infrequent due in part to the stigma associated with sexual addictions. in this sense, e-health approaches can reach a potential audience of users who would not access treatment if they had to physically visit a clinic. for this reason, the present project seeks to evaluate the efficacy of an online intervention aimed at the treatment of cybersex addiction or online sexual compulsive behavior disorder in the general population. for this purpose, a sample of 100 patients with a risk or pathological profile will be randomly assigned to an experimental (n=50) or control group (n=50) with similar characteristics. all of them will undergo an online assessment. the experimental group will receive an individualized online program of twelve one-hour sessions. the study will be based on an experimental design of comparison between groups (experimental-control) with pretest-posttest-follow-up evaluation at 1 month, 3 months, 6 months and 12 months, to evaluate the efficacy of the intervention. for this purpose, descriptive and differential statistical analyses (t-tests and repeated measures anova), cohen's d test for effect size and regression analysis will be performed.


Eligibility criteria:
inclusion criteria: * online sexual compulsive behaviors, and may or may not also have other offline sexual compulsive behaviors * any gender or sexual orientation * minimum score of 9-18 points on the internet sex screening test (isst) of delmonico (1997) in the spanish adaptation of ballester, gil, gómez and gil (2010) exclusion criteria: * coocurrence of psychotic symptoms, cognitive impairment, or other serious mental conditions

Keywords: cybersex addiction psychological treatment e-health sexual compulsivity effectiveness online sex addiction
the effect of dark chocolate and cinnamon sugars on pain and anxiety in university students with primary dysmenorrhea

Conditions: Primary Dysmenorrhea; Pain; Anxiety

Summary: aim: in this prospective, randomized controlled study, the aim of this study was to investigate the effects of dark chocolate and cinnamon sugar on pain and anxiety in university students with primary dysmenorrhea. design: the prospective, randomized controlled study


Eligibility criteria:
inclusion criteria: * university students who had not given birth, * were between the ages of 18 and 25, * had regular menstrual cycles (28±7 days), * had menstrual pain severity of 5 or more on the visual analog scale (vas) in the previous month, * had primary dysmenorrhea, gave written informed consent, * volunteered to participate in the study were included in the study. exclusion criteria: * the study included patients with hearing loss, pelvic pathology, neurological, endocrine or psychiatric disease, and chronic disease such as diabetes mellitus or heart disease, currently taking medication such as antidepressants or oral contraceptives, * menstrual irregularities, * university students who had mental problems that prevented evaluation and cooperation, obesity, malignant condition, pelvic surgery, pregnancy, analgesic use, chocolate and cinnamon allergy, * use of any nutritional supplements, medication or non-drug application (reiki, meditation, reflexology, acupressure, etc.) to reduce pain, * university students who did not volunteer to participate in the study were excluded.

Keywords: university students dark chocolate cinnamon sugar
efficacy, safety, preference and response duration of clobex® spray and taclonex® ointment in psoriasis

Conditions: Plaque Psoriasis

Summary: evaluate the efficacy of clobex® spray as compared to taclonex® ointment in terms of overall disease severity and investigator global assessment.

same as above.

Eligibility criteria:
inclusion criteria: * moderate to severe psoriasis involving 3-20% of the body surface area exclusion criteria: * subjects who have surface area involvement too large that would require more than 50 grams per week of clobex® spray or more than 100 grams per week of taclonex® ointment * subjects having psoriasis that involves the scalp, face, or groin
long term evaluation of primary congenital glaucoma management in sohag university hospital

Conditions: Primary Congenital Glaucoma

Summary: evaluation of primary congenital glaucoma management in sohag university hospital

long term evaluation of primary congenital glaucoma management in sohag university hospital

Eligibility criteria:
inclusion criteria: * children operated more than 3 months exclusion criteria: * other types of operated pediatric glaucoma

Keywords: primary congenital glaucoma
does medicinal mushroom agaricus blazei protect against allergy and asthma?

Conditions: Pollen; Allergy, Asthma

Summary: asthma and allergy is increasing in norway and western countries. treatment is still mostly symptomatic. extracts of the immunomodulatory and edible mushroom agaricus blazei, such as andosan™, have been shown to protect against asthma and allergy in murine models by changing the t helper cell 1(upregulation)-t helper cell 2 (downregulation) balance in the immune system. andosan™ is produced in japan and approved as food (mushroom juice) in norway. blood donors and possibly patients with pollen-derived allergy and asthma will be included in the study.the aim is to examine whether andosan™ i) has similar clinical effects against allergy and asthma in man as it has in mice, and ii) reduces drug use and increases frequency of blood donations. blood donors or patients who are recruited with informed consent will be given andosan™ or placebo orally as add-on treatment to ordinary treatment for 7 weeks during the birch pollen season, and specific ige will be measured before, during and after the intervention, in addition to basophil activation testing and filling out of a questionnaire.

blood donors at oslo university hospital (ouh) blood bank with self-reported birch pollen allergy and/or asthma were recruited for the study during last 4 months of 2015 and first 2 months of 2016. they signed an informed consent form for the study and were randomized into andosan™ and placebo groups. the pi (md) had the study key and the participants in the study were handled by other staff (nurses and bioengineers) at the blood bank. the participants were given a questionnaire that was filled out before and after the study. before, during and after the study also blood samples were taken for allergy testing (ige, bat) or cytokine profiles. when the participants visited the blood bank after 3.5 weeks, they brought the study medicine vessel (plastic container) that was controlled for remaining study medicine (all should have been used) and given new study medicine for the remaining study period (3.5 weeks). the participants were also asked about possible side effects of the study medicine. in the intervention arm, agaricus blazei-based mushroom extract andosan™, was given, which is produced as health food in japan and imported as food to norway and provided for the study by immunopharma company, norway. data were collected and analyzed together after the study. statistical help was solicited from an ouh statistician.

Eligibility criteria:
inclusion criteria: * blood donors with birch pollen-derived allergy and asthma exclusion criteria: * blood donors with other types of allergy and blood donors with birch pollen allergy who are would not be in southern norway during most of the pollen season
effect of acceptance and commitment therapy based interventions on mental health and cognitive impairment for patients with advanced colorectal cancer

Conditions: Acceptance and Commitment Therapy, Mental Health, Cognitive Impairment,Colorectal Cancer

Summary: the present study aims to: determine the effect of acceptance and commitment therapy-based interventions on mental health and cognitive impairment for patients with advanced colorectal cancer. research hypothesis: cancer patients who receive acceptance and commitment therapy-based interventions will exhibit better mental health and lower cognitive impairments than those who didn't receive it.

6) patients' medical charts in the unit will be reviewed to identify those who meet the inclusion criteria. patients who meet the predetermined inclusion criteria will be randomly recruited in the study. after random sampling and dividing patients into two groups of study and control. patients from the study and control groups will be interviewed individually by the researcher to apply the study tools. acceptance and commitment therapy will be carried out for patients in the study group while those in the control group will be left without any intervention to undergo the usual unit routine care. 7) the researcher was undergoing a period of training on acceptance and commitment therapy (act) through online academic training at association for contextual behavioral science (acbs) for 8 weeks with 16 credits hours'certificate by (harris, 2015). before embarking on the actual study, the researcher passed through independent teaching about acceptance and commitment therapy under the direction, guidance, and supervision of the thesis supervisors. this included a discussion of the theoretical foundation of act as well as the accuracy and appropriateness of the exercises used and needed for each session. 8) the therapy consisted of six sessions, each session of acceptance and commitment therapy was developed based on general and specific objectives. an expert professor in the nursing education field revised the act sessions' overall objectives and the specific ones. the overall objectives of each session and the content of the sessions were translated into arabic.

Eligibility criteria:
inclusion criteria: are not participating in any type of psychotherapy, score high in the cognitive impairment questionnaire.
musculoskeletal pain in patients with covid-19 who have hospital care

Conditions: Covid19

Summary: worldwide, the covid-19 pandemic continues to grow. although covid-19 mainly affects the lungs and internal organs, musculoskeletal injury from this disease was reported with the presentation of marked elevation in creatine kinase and lactate dehydrogenase levels. patients with post-acute covid-19 are considered patients with a post-intensive syndrome (pics) that results in loss of functional independence. in the physical and rehabilitation medical field, various modalities with therapeutic exercise can be used to manage pain by a physical therapist and psychiatrist. pain management is particularly important during the covid-19 pandemic because of the reduced accessibility to hospitals and medical resources.

the covid-19 survivors with pain symptoms will participated. in this phase, a face-to-face interview will be conducted to collecting all outcomes about pain.

Eligibility criteria:
inclusion criteria: * recovered from covid-19 infection. * covid-19 survivors after hospitalization. * musculoskeletal pain. exclusion criteria: * participants will be excluded also if they score greater than 6 points on the beck depression inventory (bdi) or more than 30 points in the state trait anxiety inventory (stai), dementia and not italian speaking due to the high level of language skills required for questionnaires and quantitative sensory testing. * psychiatric or neurological disorders

Keywords: covid19 pain musculoskeletal
efficacy of favipiravir against severe ebola virus disease

Conditions: Ebola Virus Disease

Summary: the purpose of this study is to explore the therapeutic efficacy of favipiravir, a broad-spectrum antiviral drug against severe cases of ebola virus disease (evd), which is the most difficult aspect for clinical management of evd due to its high fatality rate.

this is a prospective, open-label, controlled phase 2 trial of favipiravir among severe cases (cases with hemorrhage, severe dehydration, consciousness disorders, shock, and high blood viral load with ct value below 20) of confirmed evd patients in the capital area of sierra leone. patients with 13 years of age or older would be assigned in an 1:1 randomised manner to receive who-recommended therapy (mainly symptomatic and supportive therapies, control group. who, world health organization.) or oral favipiravir (1600 mg twice on the first day, followed by a twice-daily dose of 600 mg until negative blood viral load detection or death) plus who-recommended therapy (treatment group). the primary efficacy end point was case fatality rate.the secondary efficacy endpoint is blood (plasma)viral load. optimal inclusion number is 240 cases (120 for each group), but considering the actual situation of pandemic area, the front line doctors have the right to reset the inclusion number, and modify the study protocol according to the actual situation in the front.

Eligibility criteria:
inclusion criteria: * male or famale，13 -75 years of age * clinical diagnosis of evd * positive blood viral rna detection * with any one of the symptoms below: hemorrhage (including hematemesis, hemoptysis, hematochezia, hematuria, mucocutaneous hemorrhage), severe dehydration (including oliguria, anuria, feebleness, hypotension, tachycardia), consciousness disorders (including coma, delirium, confusion, convulsion), shock, and high blood viral load (ct value below 20) * not received any therapies for evd * provided written informed consent, by guardian or the patient himself * be able to administrate and tolerate oral administration of tablets exclusion criteria: * severe vomiting * pregnancy and breast-feeding * received antiviral treatment against evd
achieving portal access with scorpion post-approval study 2

Conditions: Portal Hypertension; Liver Diseases; Ascites Hepatic; Hydrothorax; Vascular Diseases

Summary: creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a tips procedure. the purpose of this study is to evaluate portal vein access sets during the tips procedure.


Eligibility criteria:
inclusion criteria: 1. scorpion or scorpion x kit introduced into the vasculature as the initial device for portal vein access exclusion criteria: 1. tips procedure was not initiated and/or no portion of the kit was introduced into the vasculature 2. inaccessible medical records

Keywords: transjugular intrahepatic portosystemic shunt tips portal vein access